160 related articles for article (PubMed ID: 24091028)
1. ALK as a paradigm of oncogenic promiscuity: different mechanisms of activation and different fusion partners drive tumors of different lineages.
Mariño-Enríquez A; Dal Cin P
Cancer Genet; 2013 Nov; 206(11):357-73. PubMed ID: 24091028
[TBL] [Abstract][Full Text] [Related]
2. Non-muscle myosin heavy chain (MYH9): a new partner fused to ALK in anaplastic large cell lymphoma.
Lamant L; Gascoyne RD; Duplantier MM; Armstrong F; Raghab A; Chhanabhai M; Rajcan-Separovic E; Raghab J; Delsol G; Espinos E
Genes Chromosomes Cancer; 2003 Aug; 37(4):427-32. PubMed ID: 12800156
[TBL] [Abstract][Full Text] [Related]
3. Development of anaplastic lymphoma kinase (ALK) small-molecule inhibitors for cancer therapy.
Li R; Morris SW
Med Res Rev; 2008 May; 28(3):372-412. PubMed ID: 17694547
[TBL] [Abstract][Full Text] [Related]
4. Targeting anaplastic lymphoma kinase in lung cancer.
Shaw AT; Solomon B
Clin Cancer Res; 2011 Apr; 17(8):2081-6. PubMed ID: 21288922
[TBL] [Abstract][Full Text] [Related]
5. Dual ALK and MYC rearrangements leading to an aggressive variant of anaplastic large cell lymphoma.
Liang X; Branchford B; Greffe B; McGavran L; Carstens B; Meltesen L; Albano EA; Quinones R; Cook B; Graham DK
J Pediatr Hematol Oncol; 2013 Jul; 35(5):e209-13. PubMed ID: 23619105
[TBL] [Abstract][Full Text] [Related]
6. Identification of anaplastic lymphoma kinase variant translocations using 5'RACE.
Hernández L; Campo E
Methods Mol Med; 2005; 115():295-314. PubMed ID: 15998975
[TBL] [Abstract][Full Text] [Related]
7. The emerging pathogenic and therapeutic importance of the anaplastic lymphoma kinase gene.
Kelleher FC; McDermott R
Eur J Cancer; 2010 Sep; 46(13):2357-68. PubMed ID: 20451371
[TBL] [Abstract][Full Text] [Related]
8. ALK-positive anaplastic large cell lymphoma with TPM3-ALK translocation.
Shin S; Kim J; Yoon SO; Kim YR; Lee KA
Leuk Res; 2012 Jul; 36(7):e143-5. PubMed ID: 22591683
[No Abstract] [Full Text] [Related]
9. Analysis of gene expression profile of TPM3-ALK positive anaplastic large cell lymphoma reveals overlapping and unique patterns with that of NPM-ALK positive anaplastic large cell lymphoma.
Bohling SD; Jenson SD; Crockett DK; Schumacher JA; Elenitoba-Johnson KS; Lim MS
Leuk Res; 2008 Mar; 32(3):383-93. PubMed ID: 17720243
[TBL] [Abstract][Full Text] [Related]
10. ATIC-ALK: A novel variant ALK gene fusion in anaplastic large cell lymphoma resulting from the recurrent cryptic chromosomal inversion, inv(2)(p23q35).
Colleoni GW; Bridge JA; Garicochea B; Liu J; Filippa DA; Ladanyi M
Am J Pathol; 2000 Mar; 156(3):781-9. PubMed ID: 10702393
[TBL] [Abstract][Full Text] [Related]
11. Amplification but not translocation of anaplastic lymphoma kinase is a frequent event in oesophageal cancer.
Schoppmann SF; Streubel B; Birner P
Eur J Cancer; 2013 May; 49(8):1876-81. PubMed ID: 23490651
[TBL] [Abstract][Full Text] [Related]
12. Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with the variant RNF213-, ATIC- and TPM3-ALK fusions is characterized by copy number gain of the rearranged ALK gene.
van der Krogt JA; Bempt MV; Ferreiro JF; Mentens N; Jacobs K; Pluys U; Doms K; Geerdens E; Uyttebroeck A; Pierre P; Michaux L; Devos T; Vandenberghe P; Tousseyn T; Cools J; Wlodarska I
Haematologica; 2017 Sep; 102(9):1605-1616. PubMed ID: 28659337
[TBL] [Abstract][Full Text] [Related]
13. The role of the ALK receptor in cancer biology.
Hallberg B; Palmer RH
Ann Oncol; 2016 Sep; 27 Suppl 3():iii4-iii15. PubMed ID: 27573755
[TBL] [Abstract][Full Text] [Related]
14. Anaplastic lymphoma kinase as a therapeutic target.
Kruczynski A; Delsol G; Laurent C; Brousset P; Lamant L
Expert Opin Ther Targets; 2012 Nov; 16(11):1127-38. PubMed ID: 22998583
[TBL] [Abstract][Full Text] [Related]
15. Novel TRAF1-ALK fusion identified by deep RNA sequencing of anaplastic large cell lymphoma.
Feldman AL; Vasmatzis G; Asmann YW; Davila J; Middha S; Eckloff BW; Johnson SH; Porcher JC; Ansell SM; Caride A
Genes Chromosomes Cancer; 2013 Nov; 52(11):1097-102. PubMed ID: 23999969
[TBL] [Abstract][Full Text] [Related]
16. [Implications of ALK (anaplastic lymphoma kinase) in oncohematology].
Cluzeau T; Pécuchet N; Mounier N; Vignot S
Bull Cancer; 2010 Aug; 97(8):991-6. PubMed ID: 20483705
[TBL] [Abstract][Full Text] [Related]
17. Targeting oncogenic ALK: a promising strategy for cancer treatment.
Grande E; Bolós MV; Arriola E
Mol Cancer Ther; 2011 Apr; 10(4):569-79. PubMed ID: 21474455
[TBL] [Abstract][Full Text] [Related]
18. The role of anaplastic lymphoma kinase in pediatric cancers.
Takita J
Cancer Sci; 2017 Oct; 108(10):1913-1920. PubMed ID: 28756644
[TBL] [Abstract][Full Text] [Related]
19. Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion.
Rimkunas VM; Crosby KE; Li D; Hu Y; Kelly ME; Gu TL; Mack JS; Silver MR; Zhou X; Haack H
Clin Cancer Res; 2012 Aug; 18(16):4449-57. PubMed ID: 22661537
[TBL] [Abstract][Full Text] [Related]
20. Intragenic anaplastic lymphoma kinase (ALK) rearrangements: translocations as a novel mechanism of ALK activation in neuroblastoma tumors.
Fransson S; Hansson M; Ruuth K; Djos A; Berbegall A; Javanmardi N; Abrahamsson J; Palmer RH; Noguera R; Hallberg B; Kogner P; Martinsson T
Genes Chromosomes Cancer; 2015 Feb; 54(2):99-109. PubMed ID: 25251827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
